Protokinetix Commences Organ Preservation Trials

VANCOUVER, British Columbia, Aug. 23, 2005 (PRIMEZONE) -- Following PKTX's (OTCBB:PKTX) successful testing of AFGP on heart cells announced July 18, 2005, the Company has just completed their initial organ preservation trials using heart tissues. The tissue that was treated with AFGP survived in contrast to the untreated tissue that suffered 100% mortality. These tests were conducted over a period of 8 hours at a temperature of 4 degrees C. An independent pathologist validated and corroborated these results.

This dramatically enhanced survivability of heart tissue treated with synthetic AFGP is a vital step toward the development of an effective media for the preservation of organs for transplantation.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887